

## Final - February 26, 2024

### MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

February 28-29, 2024

#### Wednesday, February 28, 2024

8:00	<b>Welcome &amp; Introductions</b>	Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:30	<b>COVID-19 Vaccines</b> Introduction	Dr. Matt Daley (ACIP, WG Chair)
	COVID-19-associated hospitalizations among adults - COVID-NET	Dr. Christopher Taylor (CDC/NCIRD)
	COVID-19 vaccination coverage update	Dr. Kevin Chatham-Stephens (CDC/NCIRD)
	COVID-19 vaccine effectiveness	Dr. Ruth Link-Gelles (CDC/NCIRD)
	Economic analysis of an additional dose of COVID-19 vaccine	Dr. Lisa Prosser (University of Michigan)
	Evidence to Recommendations	Dr. Megan Wallace (CDC/NCIRD)
	Next steps for the COVID-19 vaccine program	Dr. Lakshmi Panagiotakopoulos (CDC/NCIRD)
10:50	<b>Break</b>	
11:10	<b>Chikungunya Vaccines</b> Introduction	Dr. Wilbur Chen (ACIP, WG Chair)
	Update on chikungunya vaccine licensure	Dr. Susan Hills (CDC/NCEZID)
	Review of proposed policy options for chikungunya vaccine use among U.S. adults traveling abroad	Dr. Susan Hills (CDC/NCEZID)
	Review of proposed policy options for chikungunya vaccine use among laboratory workers	Dr. Susan Hills (CDC/NCEZID)
	Vaccine use among pregnant and breastfeeding women	Dr. Susan Hills (CDC/NCEZID), Dr. Dana Meaney-Delman (CDC/NCBDDD)
12:25	<b>Break</b>	
1:25	<b>DT Vaccine</b> Guidance to use Td vaccine for those instances when receipt of the pertussis component is contraindicated	Dr. Michelle Hughes (CDC/NCIRD) Dr. Jeanne Santoli (CDC/NCIRD)
1:35	<b>Break</b>	
1:40	<b>Public Comment</b>	
2:00	<b>VOTES</b> COVID-19 Vaccines	Dr. Megan Wallace (CDC/NCIRD)
	Chikungunya Vaccine	Dr. Susan Hills (CDC/NCEZID)
	<b>VFC VOTES</b> Diphtheria, Tetanus, and Pertussis	Dr. Jeanne Santoli (CDC/NCIRD)
2:30	<b>Break</b>	
2:40	<b>Influenza Vaccines</b> Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness	Dr. Aaron Frutos (CDC/NCIRD/ID)
	Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza in California, October 2023—January 2024	Dr. Sophie Zhu (California Department of Public Health and CDC/PHIC/DWD)
	Safety of LAIV4 in Children with Asthma	Dr. C. Buddy Creech (Vanderbilt University Medical Center)
	Influenza B/Yamagata Update	Dr. Lisa Grohskopf (CDC/NCIRD/ID)
4:10	<b>Break</b>	
4:20	<b>Polio Vaccines</b> Work Group deliberations on potential use of nOPV2 as an outbreak control measure in the US	Dr. Sarah Kidd (CDC/NCIRD)
	Clinical considerations for children who received fractional dose inactivated polio vaccine (fIPV) in other countries	Dr. Sarah Kidd (CDC/NCIRD)
5:10	<b>Agency Updates</b>	CMS, FDA, HRSA, IHS, OIDP, NIH
5:30	<b>Adjourn</b>	

## Final - February 26, 2024

Thursday, February 29, 2024

8:00	<b>Welcome &amp; Introductions</b>	Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:10	<b>Respiratory syncytial virus (RSV) Vaccines Adults</b>	
	Introduction	Dr. Camille Kotton (ACIP, WG Chair)
	Risk-stratified rates of RSV-associated hospitalization among adults	Dr. Rebecca Woodruff (CDC/NCCDPHP)
	Implementation update: older adult RSV vaccination	Dr. Carla Black (CDC/NCIRD)
	Post-marketing safety surveillance of older adult RSV vaccination	Dr. Tom Shimabukuro (CDC/NCIRD)
	Preliminary Analysis of Guillain-Barré Syndrome (GBS) following RSV Vaccination among adults 65 years and older	Dr. Patricia Lloyd (FDA)
	Older adult RSV vaccination: benefits and risks discussion	Dr. Michael Melgar (CDC/NCIRD)
	Overview of Moderna's Investigational RSV Vaccine (mRNA-1345) in Adults ≥60 Years of Age	Dr. Rituparna Das (Moderna)
	Work group interpretations and discussion	Dr. Amadea Britton (CDC/NCIRD)
11:10	<b>Break</b>	
11:20	<b>Meningococcal Vaccines</b>	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Revising the Adolescent Meningococcal Vaccine Schedule: Term of Reference and Considerations	Dr. Sarah Schillie (CDC/NCIRD)
	GSK Pentavalent MenABCWY vaccine: Term of Reference	Dr. Sarah Schillie (CDC/NCIRD)
12:00	<b>Break</b>	
12:45	<b>Pneumococcal Vaccines</b>	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Current epidemiology of invasive pneumococcal disease and pneumococcal vaccine coverage in adults	Mr. Ryan Gierke (CDC/NCIRD)
	Preliminary findings of the Pneumococcal pNeumonia Epidemiology, Urine serotyping, and Mental Outcomes (PNEUMO) US study	Dr. Wesley Self (Vanderbilt University Medical Center)
	Phase 3 clinical trial data of PCV21	Dr. Heather Platt (Merck)
	Post-licensure PCV20 safety data	Dr. Pedro Moro (CDC/NCEZID), Dr. Richard Forshee (FDA)
	PCV21 Policy Questions and Preliminary WG interpretations of EtR	Dr. Miwako Kobayashi (CDC/NCIRD)
3:00	<b>Break</b>	
3:10	<b>Combined Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate, and Hepatitis B vaccine (Vaxelis®)</b>	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Background on invasive Hib disease and vaccination among American Indian and Alaska Native Populations	Dr. Jennifer Collins (CDC/NCIRD)
	The HibVax Study: Immunogenicity of H. influenzae type b PRP-OMP vaccines in American Indian and Alaska Native infants	Dr. Laura Hammitt (Johns Hopkins Bloomberg School of Public Health - Center for Indigenous Health)
	Work group considerations	Dr. Jennifer Collins (CDC/NCIRD)
4:30	<b>Adjourn</b>	

**Acronyms**

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention
NCIRD	National Center for Immunization & Respiratory Diseases
NCEZID	National Center for Emerging and Zoonotic Diseases
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
WG	Work Group
WHO	World Health Organization
VE	Vaccine Effectiveness